NCT03147040
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Invasive lobular carcinoma (ILC)
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Must have diagnosis of ILC
Exclusions: Leptomeningeal disease localization
https://ClinicalTrials.gov/show/NCT03147040